APA (7th ed.) Citation

M, T., CJR, I., G, M., L, C., L, D., E, M., . . . KG, B. (2025). Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: Results from a community-based, open-label, randomized Phase III trial. Antimicrobial agents and chemotherapy, 69(8), e0005425. https://doi.org/10.1128/aac.00054-25

Chicago Style (17th ed.) Citation

M, Tate, et al. "Clinical Effectiveness, Safety, and Viral Mutagenicity of Oral Favipiravir for COVID-19: Results from a Community-based, Open-label, Randomized Phase III Trial." Antimicrobial Agents and Chemotherapy 69, no. 8 (2025): e0005425. https://doi.org/10.1128/aac.00054-25.

MLA (9th ed.) Citation

M, Tate, et al. "Clinical Effectiveness, Safety, and Viral Mutagenicity of Oral Favipiravir for COVID-19: Results from a Community-based, Open-label, Randomized Phase III Trial." Antimicrobial Agents and Chemotherapy, vol. 69, no. 8, 2025, p. e0005425, https://doi.org/10.1128/aac.00054-25.